Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib in Pediatric Relapsed/Refractory AML With FLT3-ITD Mutations
NCT03793478Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2018
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of quizartinib in acute myeloid leukemia (AML), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of dose-limiting toxicities, Composite complete remission rate and 3 more. Started Aug 2018; status: active, not recruiting.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03793478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03793478.